Serum adiponectin levels in obese type 2 diabetic patients with diabetic retinopathy

N.V. Malachkova¹, Cand Sc (Med), M.L. Kyryliuk², Dr Sc (Med), Prof., I.V. Komarovska¹, Post-grad Student

¹Pirogov National Medical University Vinnytsia (Ukraine)
²Department of Neuroendocrinology, Ukrainian Research Center for Endocrine Surgery, Transplantation of Endocrine Organs and Tissues of Ministry of Public Health of Ukraine Kyiv (Ukraine)

E-mail: natali.malachkova@mail.ru

Background. Diabetic retinopathy (DR) is one of the main complications of diabetes mellitus, the main cause of irreversible blindness in patients of working age in industrialized countries, has a high incidence rates and refers to neovascular eye diseases. At the present time, additional factors that affect the sensitivity to chronic hyperglycemia, the formation of microvascular complications, in particular, DR, include obesity and obesity-associated hormones of adipose tissue (adipokines: leptin, adiponectin, resistin, etc.).

Purpose. To investigate the serum adiponectin levels in patients at different stages of DR in type 2 diabetes mellitus (T2DM) and obesity.

Material and Methods. Study involved 99 patients, divided into 2 groups. The 1-st group (control group) consisted of 23 persons with obesity without T2DM (both male and female subjects; mean age, 57.03 ± 4.91 years), the 2-nd group consisted of 76 patients with T2DM, obesity and DR (both male and female subjects; mean age, 59.98 ± 4.17 years; mean duration of diabetes, 10.01 ± 2.81 years; mean glycated hemoglobin (HbA1C) level, 10.94 ± 2.08%), subdivided into 3 subgroups: with minimal and mild non-proliferative DR, with moderate to severe non-proliferative DR, with proliferative DR. The concentration of serum adiponectin was determined by ELISA kit. Statistical analysis included one- and two-factor analysis of variance.

Results. Patients with mild non-proliferative DR had somewhat lower (worst) adiponectin levels among patients aged 60 and below with DM subcompensation. The lowest serum adiponectin levels were common for moderate to severe non-proliferative DR among T2DM patients aged above 60 with duration of diabetes of 10 years or less and with T2DM compensation. Among T2DM patients with proliferative DR, the worst serum adiponectin levels were common for T2DM patients aged 60 and below with duration of diabetes of less than 10 years and with T2DM compensation. Considering statistic values of serum adiponectin levels for this stage, it should be noted that, for conditionally combined proliferative DR with severe and moderate DR, statistically significant changes (p=0.007) consisted in the decreased serum adiponectin levels in T2DM compensation.

Conclusions. Minimal and mild non-proliferative DR is characterized by a significant lower serum adiponectin level compared with the subsequent stages in subcompensation of T2DM.

Key-words: diabetic retinopathy, type 2 diabetes mellitus, obesity, adiponectin.

Background

Our previous studies on the state of carbohydrate metabolism and insulin resistance in patients with diabetic retinopathy (DR) in type 2 diabetes mellitus (T2DM) and obesity have shown that all patients with DR had chronic hyperglycemia with decompensated T2DM and the greatest proportion of patients with adverse indices of insulin resistance and with reduced sensitivity to insulin had proliferative DR [23]. According to the literature, in DR patients, hyperglycemia can induce the damage of retinal vascular endothelial cells, ischemia and adhesion of leukocytes to vascular endothelium [29, 30], synthesis of proangiogenic factors and cytokine excess, which results in small vessel functioning disorders and abnormal neovascular formations [10]. One of these cytokines is an adipose tissue-secreted adipokine, in particular adiponectin, modulating metabolic response.

© Malachkova N.V., Kyryliuk M.L., Komarovska I.V., 2017
The absence of adiponectin in mice has been found to develop the insulin resistance, obesity, hyperglycemia, arterial hypertension and endothelial dysfunction [21, 25]. There are clinical studies on screening the relationship between plasma adiponectin concentration and DR severity [11, 24]. However, it is not always easy to interpret the findings of the adiponectin level test in T2DP patients with DR, which is associated with various test designs and methodological approaches to evaluating the hormone’s concentration in blood.

The purpose of the present paper was to study serum adiponectin levels in obese type 2 diabetes mellitus and different stages of diabetic retinopathy.

**Material and Methods**

Ninety-nine patients (112 eyes), divided into two groups, were involved in the study. Group 1 (controls) consisted of 23 overweight or obese persons without T2DM (both male and female subjects; mean age, 57.03±4.91); Group 2 comprised 76 obese T2DM patients with DR (both male and female subjects; mean age, 59.98±4.17; mean DM duration, 10.01±2.81 years; mean glycated hemoglobin (HbA1C) level, 10.94±2.08%). Inclusion criteria were age >18; T2DM; DR; and obesity (or overweight). Exclusion criteria were an endocrine and somatic disease leading to obesity; acute infectious disease; type 1 diabetes mellitus; cancer; comorbidity decompensation; mental disorders; administration of neuroleptics and antidepressants; proteinuria; clinically significant maculopathy; optic nerve damage; glaucoma; and cataract. The study followed the tenets of the Declaration of Helsinki of the World Medical Association (Seoul, 2008) and corresponding orders of Ministry of Health of Ukraine (No 281 dated November, 01, 2000; No 355 dated September, 25, 2002; No1118 dated December, 21, 2012). Obesity in the groups was defined using body mass index (BMI). Analysis of serum adiponectin levels was performed using SPSS 9.0 (SPSS Inc., Chicago, IL, USA).

**Results**

One-way and two-way ANOVA was used to analyze serum adiponectin levels in T2DM obese patients depending on the stage of diabetic retinopathy. Mean serum adiponectin levels in the groups are given in Table 1. It should be noted that mean serum adiponectin levels in all groups were below reference ranges for non-obese patients, males and females. ANOVA showed no statistical difference in mean serum adiponectin levels among patients in Control group and in Subgroups 2A and 2B with a certain decrease in its level in Subgroup 2A.

A post-hoc two-way ANOVA to test for the effects of patient’s age, duration of diabetes, HbA1C level and type of glycemic control therapy revealed a number of details (Table 2).

The minimal values for mean serum adiponectin levels among patients aged 60 and below were observed in patients with proliferative DR whereas among patients aged above 60, they were observed in patients of Subgroup 2B. Additionally, the minimal (worst) values for mean serum adiponectin levels (and their CIs) were observed in patients below 60 with proliferative DR and the maximal (best) values for mean serum adiponectin levels were also observed in proliferative DR in patients above 60. Mean serum adiponectin levels trended to be increased in the patients aged 60 and below compared with the older group.

Analysis of serum adiponectin levels in patients with different stages of DR in dependence on the duration of diabetes showed the lowest values for mean serum adiponectin levels among patients with duration of diabetes of less than 10 years (and CIs) in Subgroups 2B and 2C and among patients with duration of diabetes of more than 10 years in Subgroup 2A. The highest mean serum adiponectin levels were noted in proliferative DR patients with duration of diabetes of more than 10 years.

The lowest mean serum adiponectin levels (hypoadiponectinemia) among diabetic patients with HbA1C ≤ 8% were observed in patients of Subgroup 2A, whereas among diabetic patients with HbA1C > 8% they were observed in patients of Subgroup 2B. And the lowest (worst) serum adiponectin level was noted in patients with HbA1C > 8% of Subgroup 2B, whereas the highest (best) one was observed in patients with HbA1C ≤ 8% of Subgroup 2B. Statistically significant difference (p=0.007) was revealed when comparing Subgroup 2A with Subgroup 2B+2C for HbA1C ≤ 8%, 0.38±0.09 µg/ml vs 0.89±0.14 µg/ml, respectively, (p=0.007) and
when comparing Subgroups 2B+2C for HbA1C ≤ 8% and HbA1C > 8%, 0.89±0.14 µg/ml vs 0.39±0.11 µg/ml, respectively, \( (p=0.007) \). Decreased serum adiponectin levels among diabetic patients with HbA1C > 8% could advance the mild non-proliferative stage of diabetic retinopathy to subsequent stages.

A type of glycemic control therapy for T2DM did not have statistically significant effect on mean serum adiponectin levels in all DR stages studied. The lowerest values of mean serum adiponectin levels among patients with type 1 and type 2 glycemic control therapy (oral glycemic control agents) were observed in Subgroup 2A and among patients with type 3 glycemic control therapy (metformin and insulin therapy) they were observed in proliferative DR patients of Subgroup 2C. In general, the best (highest) mean serum adiponectin levels were observed in proliferative DR patients taking tablet agents and the worst ones were in patients getting insulin therapy.

**Discussion**

Diabetic retinopathy is one of the main complications of diabetes mellitus and the leading course of blindness in working age persons in developed industrial countries \[32\]. DR has high incidence rates and refers to neovascular eye diseases including retrolental fibroplasias (retinopathy of prematurity) and age-related macular degeneration, in which new vascular formation occurs under hypoxia or metabolic abnormalities which affect energy transfer. A lot of factors (insufficient control of blood glucose level, hypertony, dyslipidemia) have been found to have an effect on progression of diabetic retinopathy; kidney diseases are also important in this regard and can contribute to DR development \[14, 18, 34\].

Although the duration is the most important risk factor (as for DR) \[14\], not all patients with insufficient glycemic control developed retinopathy (especially its proliferative stage) over time. And, contrary, strict glycemic control is not always able to prevent from DR development. However, researchers share the same opinion that duration of diabetes mellitus and degree (severity) of hyperglycemia are the main risk factors for DR development \[2\]. Results of some studies using a family cluster principle assume that there are additional components that have an effect on sensitivity to chronic hyperglycemia, in particular, a hereditary factor \[7\] and, based on to-date data, hormones of adipose tissue (leptin, adiponectin, resistin, etc.).

Adiponectin (APN, also called Acrp30, apM1) is a protein which is secreted by adipocytes, with the most abundant gen transcript 1 (apM1) \[22\], plays an important role in formation of antiatherogenic anti-inflammatory agents and insulin \[6, 8, 31, 33\], controls insulin sensitivity of tissues, and can also be involved in non-specific inflammation process \[16, 17, 36\], being a significant modulator of metabolic disorders and vascular diseases.

Our analysis of the hormonal predictors (like adiponectin, an adipose tissue-specific hormone) of diabetic retinopathy development revealed that patients with mild non-proliferative DR had somewhat lower (worst) adiponectin levels among patients aged 60 and below with DM subcompensation. The lowest serum adiponectin levels were common for moderate to severe non-proliferative DR among T2DM patients aged above 60 with duration of diabetes of 10 years or less and with T2DM compensation. Among T2DM patients with proliferative DR, the worst serum adiponectin levels were common for T2DM patients aged 60 and below with duration of diabetes of less than 10 years and with T2DM compensation. Considering statistic values of serum adiponectin levels for this stage, it should be noted that, for conditionally combined proliferative DR and severe and moderate non-proliferative DR, statistically significant changes \( (p=0.007) \) consisted in the decreased serum adiponectin levels in T2DM compensation.

Analyzed the finding of the present study, we can conclude that the decreased adiponectin levels are common for all stages of DR and have somewhat distribution characteristics due to risk factors and a stage of the disease. The absence of the protective effect of adiponectin makes vascular walls unprotected, which may contribute to DR development at early stage (mild proliferative DR) in patients aged below 60 and enhance the pathogenic effect of chronic hyperglycemia at later DR stages when hyperglycemia control is worsened.

Since adiponectin has an anti-inflammatory effect and can increase glucose tolerance levels, we believe that hypo-adiponectinemia can contribute to pathogenesis of T2DM and development of vascular complications \[5, 9\]. An interesting fact is that diabetes sensitivity locus in human is located on 3q27 chromosome where an adiponectin gene is placed \[35\]. Impaired adiponectin secretion causes increased insulin resistance \[19\]; adiponectin gene polymorphisms are associated with retinopathy in diabetic patients \[37\].

Based on the to-date data in the literature, plasma adiponectin concentrations get reduced in obesity, insulin resistance, T2MD, ischemic heart disease, and arterial hypertension \[1, 4, 12, 15, 20\], which completely correlates with our findings. Adiponectin receptor 2, AdipoR2, (but not AdipoR1) reduces vascular changes caused by ischemic heart disease \[28\]. Some studies have shown that adiponectin has anti-inflammatory features and, thus, can inhibit atherogenesis \[8, 26, 27\]. Adiponectin dose-dependently inhibits tumor necrosis factor, stimulates monocye adhesion to the arterial endothelium in human \[27\]. Besides, adiponectin inhibits binding and macrophage uptake of oxidized low density lipoproteins (LDL) \[26\]. Decreased adiponectin levels can stimulate the oxidase activity of nicotinamide adenine dinucleotide phosphate (NADPH) in human arterial walls, which leads to DR development \[3\]. The data presented above give reason to believe that adiponectin can have a protective action against development of diabetic vascular complications.
In general, adiponectin can be considered as a useful marker of insulin resistance, a modulator of main DR drivers, and a pleiotropic effect agent. In DR, adiponectin can also serve as a marker of retinal damage since it is a mediator of angiogenesis and its increased level in certain cases can also be assessed as a marker of adiponectin resistance [16] (like leptin resistance).

**Conclusions**

1. Hypoadiponectinemia is common for all DR stages in obese patients with type 2 diabetes mellitus.
2. One-way ELISA showed confidence interval of 0.35-0.73 µg/ml for serum adiponectin levels in obese T2DP patients with DR.
3. Mild non-proliferative DR is characterized by significantly lower serum adiponectin levels compared to subsequent stages in T2DM subcompensation.

**References:**


Table 1. Serum adiponectin levels (µg/ml) in patients with type 2 diabetes mellitus and different stages of diabetic retinopathy

<table>
<thead>
<tr>
<th>Subgroups of patients with diabetic retinopathy</th>
<th>Non-diabetic individuals with obesity (controls)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean serum adiponectin levels, µg/ml</td>
<td>Mean serum adiponectin levels, µg/ml</td>
</tr>
<tr>
<td>Control group (41 patients)</td>
<td>Control group (41 patients)</td>
</tr>
<tr>
<td>Subgroup 2A (23 individuals)</td>
<td>Subgroup 2B (19 patients)</td>
</tr>
<tr>
<td>Subgroup 2C (18 patients)</td>
<td>Subgroup 2C (18 patients)</td>
</tr>
<tr>
<td>Non-diabetic individuals with obesity (controls)</td>
<td>0.51 ± 0.07 (95% CI, 0.41 to 0.61)</td>
</tr>
<tr>
<td>Subgroup 2A (41 patients)</td>
<td>0.47 ± 0.05 (95% CI, 0.39 to 0.54)</td>
</tr>
<tr>
<td>Subgroup 2B (19 patients)</td>
<td>0.51 ± 0.11 (95% CI, 0.35 to 0.67)</td>
</tr>
<tr>
<td>Subgroup 2C (18 patients)</td>
<td>0.56 ± 0.12 (95% CI, 0.39 to 0.73)</td>
</tr>
</tbody>
</table>

Notes: CI – confidence interval

Table 2. Type 2 diabetes mellitus risk factors-dependant serum adiponectin levels (µg/ml) in patients with type 2 diabetes mellitus and different stages of diabetic retinopathy

<table>
<thead>
<tr>
<th>T2DM risk factors for comparison</th>
<th>Subgroups of patients with diabetic retinopathy</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Subgroup 2A</td>
</tr>
<tr>
<td>Patient age ≤ 60 years</td>
<td>n=24</td>
</tr>
<tr>
<td></td>
<td>0.38± 0.08 (95% CI, 0.23 to 0.54)</td>
</tr>
<tr>
<td>Patient age &gt; 60 years</td>
<td>n=17</td>
</tr>
<tr>
<td></td>
<td>0.58 ± 0.08 (95% CI, 0.43 to 0.74) p= 0.1</td>
</tr>
<tr>
<td>Diabetes duration ≤ 10 years</td>
<td>n=29</td>
</tr>
<tr>
<td></td>
<td>0.43± 0.06 (95% CI, 0.31 to 0.54)</td>
</tr>
<tr>
<td>Diabetes duration &gt;10 years</td>
<td>n=12</td>
</tr>
<tr>
<td></td>
<td>0.57 ± 0.09 (95% CI, 0.38 to 0.77)</td>
</tr>
<tr>
<td>HbA1C≤ 8%</td>
<td>n=14</td>
</tr>
<tr>
<td></td>
<td>0.38 ± 0.09 (95% CI, 0.21 to 0.56)</td>
</tr>
<tr>
<td>HbA1C&gt;8%</td>
<td>n=27</td>
</tr>
<tr>
<td></td>
<td>0.51± 0.06 (95% CI, 0.39 to 0.63)</td>
</tr>
<tr>
<td>Glycemic control therapy (type 1+2 therapy)</td>
<td>n=26</td>
</tr>
<tr>
<td></td>
<td>0.43 ± 0.07 (95% CI, 0.29 to 0.56)</td>
</tr>
<tr>
<td>Glycemic control therapy (type 3 therapy)</td>
<td>n=15</td>
</tr>
<tr>
<td></td>
<td>0.53± 0.08 (95% CI, 0.356 to 0.70)</td>
</tr>
</tbody>
</table>

Note: n – number of patients in subgroups, CI – confidence interval , p – significance level (F-test) for the comparison with patients aged 60 years and below